Coexistence of autoimmune bullous diseases (AIBDs) and psoriasis: A series of 145 cases - 17/06/15
Abstract |
Background |
Many case reports have described the coexistence of autoimmune bullous diseases (AIBDs) and psoriasis. Among them, anti-laminin γ1 (p200) pemphigoid is the best known.
Objectives |
We sought to characterize patients with AIBDs and psoriasis and to investigate common AIBDs occurring in these patients.
Methods |
This retrospective study included 145 patients with coexisting AIBD and psoriasis given a diagnosis from January 1, 1996, to July 31, 2013, at an academic dermatology department. Of these, 134 were consultation cases regarding AIBD diagnosis.
Results |
Ratio of male to female patients was 5.7:1. Psoriasis onset preceded AIBD onset in most patients. Mean age at AIBD onset was 65.4 years, and mean duration between psoriasis and AIBD onset was 14.6 years. Most cases had single AIBD, whereas 16 cases had combined AIBDs. Bullous pemphigoid was the most prevalent (63.4%) followed by anti-laminin γ1 pemphigoid (37.2%).
Limitations |
Consultation cases may not have included mild AIBD cases.
Conclusion |
This study confirmed the association of psoriasis and anti-laminin γ1 pemphigoid. However, because bullous pemphigoid is a much more common disease, it is seen more frequently in patients with psoriasis than anti-laminin γ1 pemphigoid.
Le texte complet de cet article est disponible en PDF.Key words : anti-laminin γ1 (p200) pemphigoid, autoimmune bullous disease, bullous pemphigoid, psoriasis, psoriasis vulgaris, pustular psoriasis
Abbreviations used : AIBD, BMZ, BP, IL, PF, UV
Plan
| Dr Fukuda is currently affiliated with Fukuhada Dermatology Clinic, Fukuoka, Japan. |
|
| Supported by Grants-in-Aid for Scientific Research (No. 20390308, 20591331, 21659271, 23591634, 23791298, 23791299, 23791300, 23791301, 24659534, 24591672, 24591640, 24791185), and Supported Program for the Strategic Research Foundation at Private Universities 2011-2015 from the Ministry of Education, Culture, Sports, Science, and Technology; and by Research on Measures for Intractable Diseases Project: matching fund subsidy (H23-028 to K. Iwatsuki, and H24-038 to T. Hashimoto) from the Ministry of Health, Labor, and Welfare. The study was also supported by grants from the Kaibara Morikazu Medical Science Promotion Foundation, Ishibashi Foundation, Kanae Foundation for the Promotion of Medical Science, Takeda Science Foundation, Chuo Mitsui Trust and Banking Company Ltd, and Nakatomi Foundation. |
|
| Conflicts of interest: None declared. |
Vol 73 - N° 1
P. 50-55 - juillet 2015 Retour au numéro
Article précédent
- Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
- Kim Papp, Kristian Reich, Craig L. Leonardi, Leon Kircik, Sergio Chimenti, Richard G.B. Langley, ChiaChi Hu, Randall M. Stevens, Robert M. Day, Kenneth B. Gordon, Neil J. Korman, Christopher E.M. Griffiths
- Systemic granulocyte colony-stimulating factor (G-CSF) enhances wound healing in dystrophic epidermolysis bullosa (DEB): Results of a pilot trial
- Jo-David Fine, Becky Manes, Haydar Frangoul
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?